Search results for "modality"

showing 10 items of 651 documents

Increased efficacy of stereotactic ablative radiation therapy after bevacizumab in lung oligometastases from colon cancer.

2018

Aim: Metastases from colorectal cancer are poorly responsive to stereotactic ablative radiation therapy (SABR) due to intratumoral hypoxia. Intratumoral oxygenation is improved by administration of angiogenesis inhibitors. Thus, there could be a clinical synergistic effect of SABR with bevacizumab on metastases from colorectal cancer. The aim of this study was to evaluate the feasibility and efficacy of SABR after bevacizumab in lung oligometastases from colon cancer. Methods: The data of patients with lung metastases from colon cancer who underwent SABR were retrospectively evaluated according to the following inclusion criteria: number of metastases ≤3; lung oligometastases from colon can…

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyLung NeoplasmsBevacizumabColorectal cancermedicine.medical_treatmentSABR volatility modelRadiosurgery03 medical and health sciences0302 clinical medicineInternal medicineAblative casemedicineHumansAgedRetrospective StudiesLungbusiness.industryGeneral MedicineOxygenationMiddle Agedmedicine.diseaseCombined Modality TherapyRadiation therapyBevacizumab030104 developmental biologymedicine.anatomical_structureOncology030220 oncology & carcinogenesisColonic Neoplasmsbusinessmedicine.drugTumori
researchProduct

Combinaisons de chimiothérapie ou de radiothérapie et d’inhibiteurs de checkpoints

2018

Les progrès récents de l’immunothérapie en oncologie dus au développement des anticorps anti-PD1/PDL1 révolutionnent la prise en charge des patients. Malgré tout, l’efficacité de ces traitements en monothérapie est limitée à une sous-population représentant environ 25 à 30 % des patients dans la plupart des indications. Le développement de nouvelles stratégies se base sur les combinaisons entre les traitements standards (chimiothérapie cytotoxique et radiothérapie) et l’immunothérapie afin de trouver des combinaisons synergiques.

0301 basic medicineOncologyChemotherapymedicine.medical_specialtybusiness.industrymedicine.medical_treatmentImmune checkpoint inhibitorsCancerImmunotherapyCytotoxic chemotherapymedicine.diseaseGeneral Biochemistry Genetics and Molecular BiologyRadiation therapy03 medical and health sciences030104 developmental biology0302 clinical medicineCancer immunotherapy030220 oncology & carcinogenesisInternal medicinemedicineCombined Modality TherapybusinessBiologie Aujourd'hui
researchProduct

Checkpoint inhibitors for gastroesophageal cancers: dissecting heterogeneity to better understand their role in first-line and adjuvant therapy

2020

Gastroesophageal adenocarcinoma (GEA) and squamous esophageal cancer (ESCC) are responsible for1 million deaths annually globally. Until now, patients with metastatic GEA and ESCC could anticipate survival of1 year. Anti- programmed cell death protein 1 (anti-PD-1) monotherapy has demonstrated modest efficacy in previously treated GEA and ESCC. In 2020, four pivotal trials have established anti-PD-1 therapy as a new standard of care for selected GEA and ESCC patients as first-line advanced and adjuvant therapy. In this review, we discuss the recent results of the CheckMate 649, ATTRACTION-4, KEYNOTE-590 and CheckMate 577 trials. We consider these results in the context of current standards …

0301 basic medicineOncologymedicine.medical_specialty2019-20 coronavirus outbreakEsophageal Neoplasmsmedicine.medical_treatmentImmune checkpoint inhibitorsFirst lineAntibodies Monoclonal Humanized03 medical and health sciences0302 clinical medicineStomach NeoplasmsChemoimmunotherapyInternal medicinemedicineAdjuvant therapyHumansneoplasmsGastroesophageal adenocarcinomabusiness.industryHematologyImmunotherapyEsophageal cancermedicine.diseaseCombined Modality Therapydigestive system diseasesNivolumab030104 developmental biologyOncology030220 oncology & carcinogenesisbusinessAnnals of Oncology
researchProduct

Immunotherapy of colorectal cancer: New perspectives after a long path

2016

Although significant therapeutic improvement has been achieved in the last 10 years, the survival of metastatic colorectal cancer patients remains in a range of 28 to 30 months. Presently, systemic treatment includes combination chemotherapy with oxaliplatin and/or irinotecan together with a backbone of 5-fluorouracil/levofolinate, alone or in combination with monoclonal antibodies to VEGFA (bevacizumab) or EGF receptor (cetuximab and panitumumab). The recent rise of immune checkpoint inhibitors in the therapeutic scenario has renewed scientific interest in the investigation of immunotherapy in metastatic colorectal cancer patients. According to our experience and view, here, we review the…

0301 basic medicineOncologymedicine.medical_specialtyBevacizumabColorectal cancermedicine.medical_treatmentImmunologycolorectal cancerthymidylate synthasechemotherapyCancer Vaccines03 medical and health sciences0302 clinical medicineCostimulatory and Inhibitory T-Cell ReceptorsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineAnimalsHumansPanitumumabImmunology and AllergyMolecular Targeted Therapyimmune-modulating strategieImmunotherapy metastatic colorectal cancer monoclonal antibodies target therapyCetuximabbusiness.industrytarget therapymetastatic colorectal cancercarcinoembryonic antigenAntibodies MonoclonalCancerCombination chemotherapyimmune-modulating strategiesImmunotherapymedicine.diseaseCombined Modality Therapy030104 developmental biologyOncology030220 oncology & carcinogenesisCancer vaccineImmunotherapymonoclonal antibodiesColorectal Neoplasmsbusinesscancer vaccinemedicine.drug
researchProduct

The role of chemotherapy in localized and locally advanced rectal cancer: A systematic revision

2017

Curative treatment of rectal cancer depends on an optimal surgical resection, with the addition of neoadjuvant radiotherapy (RT) with or without concomitant chemotherapy (ChT) in more advanced tumors. The role of adjuvant ChT is controversial and a more intensified neoadjuvant approach with the addition of ChT before or after RT, or even as single modality, is currently being explored in trials. A systematic review selecting randomised phase II and III trials on the role of ChT in localized rectal cancer was performed. Data show that neoadjuvant ChRT improves locoregional control in resected rectal cancer. Short-course RT (SCRT) could give similar outcomes to ChRT. The addition of oxaliplat…

0301 basic medicineOncologymedicine.medical_specialtyColorectal cancermedicine.medical_treatmentAntineoplastic Agents03 medical and health sciences0302 clinical medicineClinical Trials Phase II as TopicPreoperative chemoradiationInternal medicineMedicineCombined Modality TherapyHumansRadiology Nuclear Medicine and imagingRectal cancerNeoadjuvant therapyRandomized Controlled Trials as TopicChemotherapybusiness.industryRectal NeoplasmsGeneral MedicineAdjuvant chemotherapy; Preoperative chemoradiation; Rectal cancermedicine.diseaseCombined Modality TherapyNeoadjuvant TherapyOxaliplatinAdjuvant chemotherapyRadiation therapy030104 developmental biologyOncologyClinical Trials Phase III as Topic030220 oncology & carcinogenesisConcomitantRadiotherapy AdjuvantbusinessAdjuvantmedicine.drug
researchProduct

Nano-Enhanced Cancer Immunotherapy: Immunology Encounters Nanotechnology

2020

Cancer immunotherapy utilizes the immune system to fight cancer and has already moved from the laboratory to clinical application. However, and despite excellent therapeutic outcomes in some hematological and solid cancers, the regular clinical use of cancer immunotherapies reveals major limitations. These include the lack of effective immune therapy options for some cancer types, unresponsiveness to treatment by many patients, evolving therapy resistance, the inaccessible and immunosuppressive nature of the tumor microenvironment (TME), and the risk of potentially life-threatening immune toxicities. Given the potential of nanotechnology to deliver, enhance, and fine-tune cancer immunothera…

0301 basic medicinePD-L1medicine.medical_treatmentimmune checkpoint inhibitorNanotechnologyReviewmacrophage03 medical and health sciencesMice0302 clinical medicineImmune systemDrug Delivery SystemsCancer immunotherapyPD-L1NeoplasmsPD-1MedicineAnimalsHumansNanotechnologytumor microenvironmentTreatment resistanceAdverse effecttoll like receptor (TLR)lcsh:QH301-705.5Tumor microenvironmentbiologybusiness.industryCancerGeneral Medicinemedicine.diseaseCombined Modality TherapyImmune therapy030104 developmental biologylcsh:Biology (General)030220 oncology & carcinogenesissiRNAbiology.proteinCAR T cell therapymyeloid derived suppressor cells (MDSC)Immunotherapybusinessbi-specific antibody therapyCells
researchProduct

Guidelines are silver, but a multidisciplinary team discussion may be golden?

2018

0301 basic medicinePatient Care TeamMedical educationCarcinoma HepatocellularSilverHepatologybusiness.industryLiver NeoplasmsMultidisciplinary teamCombined Modality Therapy03 medical and health sciences030104 developmental biology0302 clinical medicineMedicineHumans030211 gastroenterology & hepatologybusinessLiver international : official journal of the International Association for the Study of the Liver
researchProduct

Cell stimulation versus cell death induced by sequential treatments with pulsed electric fields and cold atmospheric pressure plasma

2018

Pulsed electric fields (PEFs) and cold atmospheric pressure plasma (CAP) are currently both investigated for medical applications. The exposure of cells to PEFs can induce the formation of pores in cell membranes and consequently facilitate the uptake of molecules. In contrast, CAP mainly acts through reactive species that are generated in the liquid environment. The objective of this study was to determine, if PEFs combined with plasma-treated cell culture medium can mutually reinforce effects on viability of mammalian cells. Experiments were conducted with rat liver epithelial WB-F344 cells and their tumorigenic counterpart WB-ras for a direct comparison of non-tumorigenic and tumorigenic…

0301 basic medicinePlasma GasesCell MembranesCancer Treatmentlcsh:MedicineMechanical Treatment of Specimens0302 clinical medicineElectricityNeoplasmsMedicine and Health SciencesEnzyme assaysColorimetric assayslcsh:ScienceBioassays and physiological analysisCells CulturedMTT assayMultidisciplinaryChemistryPhysicsElectroporationKetonesrespiratory systemCombined Modality TherapyChemistryElectroporationMembraneOncologySpecimen DisruptionElectric Field030220 oncology & carcinogenesisPhysical SciencesBiological CulturesCellular Structures and OrganellesResearch ArticlePyruvateCell typeProgrammed cell deathCell SurvivalElectric Stimulation TherapyAtmospheric-pressure plasmaResearch and Analysis Methods03 medical and health sciencesCell Line TumorAnimalsHumansMTT assayCell ProliferationCell growthlcsh:RChemical CompoundsBiology and Life SciencesEpithelial CellsCell BiologyCell CulturesCulture MediaRats030104 developmental biologyCytostaticsSpecimen Preparation and TreatmentCell cultureBiochemical analysisBiophysicslcsh:QAcidsPLOS ONE
researchProduct

Automatic sleep scoring: A deep learning architecture for multi-modality time series

2020

Background: Sleep scoring is an essential but time-consuming process, and therefore automatic sleep scoring is crucial and urgent to help address the growing unmet needs for sleep research. This paper aims to develop a versatile deep-learning architecture to automate sleep scoring using raw polysomnography recordings. Method: The model adopts a linear function to address different numbers of inputs, thereby extending model applications. Two-dimensional convolution neural networks are used to learn features from multi-modality polysomnographic signals, a “squeeze and excitation” block to recalibrate channel-wise features, together with a long short-term memory module to exploit long-range co…

0301 basic medicineProcess (engineering)Computer sciencePolysomnographyPolysomnographyMachine learningcomputer.software_genreuni (lepotila)03 medical and health sciencesDeep Learning0302 clinical medicinepolysomnographymedicineHumansBlock (data storage)Sleep Stagesmedicine.diagnostic_testArtificial neural networksignaalinkäsittelybusiness.industryunitutkimusGeneral NeuroscienceDeep learningdeep learningsignaalianalyysiElectroencephalographyautomatic sleep scoringmulti-modality analysiskoneoppiminen030104 developmental biologyMemory moduleSleep StagesArtificial intelligenceSleepTransfer of learningbusinesscomputer030217 neurology & neurosurgeryJournal of Neuroscience Methods
researchProduct

Quality of Life in NSCLC Survivors - A Multicenter Cross-Sectional Study.

2019

The objective was to assess quality of life (QoL) in lung cancer survivors, compare it to the general population, and identify factors associated with global QoL, physical functioning, emotional functioning, fatigue, pain, and dyspnea.Data from NSCLC patients who had survived 1 year or longer after diagnosis were collected cross-sectionally in a multicenter study. QoL was assessed with the European Organisation for the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-C30 and the lung cancer module QLQ-LC13 across different clinical subgroups and compared to age- and sex-standardized general population reference values. Multivariable linear regression analyses wer…

0301 basic medicinePulmonary and Respiratory MedicineAdultMalemedicine.medical_specialtyLung NeoplasmsCross-sectional studyPopulation03 medical and health sciences0302 clinical medicineQuality of lifeInternal medicineCarcinoma Non-Small-Cell LungSurveys and QuestionnairesMedicineHumansSurvivorsLung cancereducationAgedAged 80 and overeducation.field_of_studybusiness.industryCancerMiddle Agedmedicine.diseasePrognosisCombined Modality TherapyhumanitiesSurvival Rate030104 developmental biologyCross-Sectional StudiesOncologyMulticenter study030220 oncology & carcinogenesisQuality of LifePatient-reported outcomeFemaleActive treatmentbusinessFollow-Up StudiesJournal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
researchProduct